TARS

Tarsus to Participate in Upcoming Investor Conferences

Retrieved on: 
Mercredi, mai 29, 2024
TARS, Tarsus, Patient, Science

ET

Key Points: 
  • ET
    Jeff Farrow, Chief Financial and Chief Strategy Officer, and Aziz Mottiwala, Chief Commercial Officer, will participate in an in-person fireside chat on Wednesday, June 5, 2024, at 12 p.m. PT / 3 p.m.
  • ET
    Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, and Jeff Farrow, Chief Financial and Chief Strategy Officer, will participate in an in-person fireside chat on Monday, June 10, 2024, at 11 a.m. PT / 2 p.m.
  • ET
    Live webcasts and additional information about the webcasts can be accessed on the events section of the Tarsus website .
  • Replays of the webcasts will be available on the Tarsus website within 48 hours and will be archived for a limited time.

Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference

Retrieved on: 
Jeudi, mai 9, 2024
TARS, Science, Tarsus, Patient, Bank, Conference

IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the 2024 Bank of America Healthcare Conference taking place in Las Vegas, NV, on Wednesday, May 15, at 1:55 p.m. PT / 4:55 p.m.

Key Points: 
  • IRVINE, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that Bobak Azamian, M.D., Ph.D., Chief Executive Officer and Chairman, will participate in an in-person fireside chat at the 2024 Bank of America Healthcare Conference taking place in Las Vegas, NV, on Wednesday, May 15, at 1:55 p.m. PT / 4:55 p.m.
  • ET.
  • A live webcast and additional information about the presentation can be accessed on the events section of the Tarsus website .
  • The replay will be available on the Tarsus website within 48 hours and will be archived for a limited time.

Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements

Retrieved on: 
Mercredi, mai 8, 2024
Research, Akhtar, Science, Patient, TARS, Pharmaceutical industry

IRVINE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the first quarter ended March 31, 2024.

Key Points: 
  • IRVINE, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced financial results for the first quarter ended March 31, 2024.
  • Research and development (R&D) expenses were $12.1 million for the first quarter of 2024 compared to $12.4 million for the same period in 2023.
  • Net loss for the first quarter of 2024 was $35.7 million, compared to a net loss of $23.4 million for the same period in 2023.
  • Tarsus will host a conference call and webcast to discuss its first quarter 2024 financial results and business highlights today, May 8, 2024, at 1:30 p.m. P.T.

Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon

Retrieved on: 
Mardi, avril 23, 2024
Investment, LP, Security (finance), Science, Patient, Finance Secretary (India), TARS

Net proceeds to the Company at closing will be approximately $40 million following the repayment of the existing credit facility, as well as fees and expenses associated with the transaction.

Key Points: 
  • Net proceeds to the Company at closing will be approximately $40 million following the repayment of the existing credit facility, as well as fees and expenses associated with the transaction.
  • The credit facility bears interest at a floating rate based upon the secured overnight financing rate (SOFR), plus a margin of 6.75% per annum.
  • There is no warrant coverage to the lenders and no financial covenants associated with the financing.
  • Pharmakon Advisors, LP is a leading investor in non-dilutive debt for the life sciences industry and is the investment manager of the BioPharma Credit funds.

Tarsus to Participate at Upcoming Investor Conferences

Retrieved on: 
Mardi, mars 5, 2024
Tarsus, TARS, Science, Conference, Patient, Telluride, Management

ET

Key Points: 
  • ET
    Barclays Global Healthcare Conference (Miami, FL)
    Jeff Farrow, Chief Financial Officer and Chief Strategy Officer, and Sesha Neervannan, Chief Operating Officer, will participate in a fireside chat on Tuesday, March 12, 2024, at 12:05 p.m. PT / 3:05 p.m.
  • Please check the Tarsus website for the latest information.
  • A live webcast of the fireside chats will be available on the events section of the Tarsus website.
  • The replay will be available within 48 hours and will be archived for a limited time.

Tarsus Introduces “Mite Party” Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis

Retrieved on: 
Mardi, mars 5, 2024
Education, Inflammation, FDA, Irritation, MITES, Blepharitis, OD, Patient, Disease, Eyelid, Diagnosis, Science, Infestation, Human, TARS, Pharmaceutical industry

“Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.

Key Points: 
  • “Mite Party” is designed to elevate consumer awareness of Demodex blepharitis through relatable messaging and compelling visuals to encourage patients who may have Demodex blepharitis to seek out an eye care provider for screening.
  • “We are committed to increasing Demodex blepharitis education and awareness so that patients more effectively understand their disease and are motivated to seek treatment,” said Aziz Mottiwala, Chief Commercial Officer of Tarsus.
  • We look forward to advancing this novel campaign with the goal of helping as many patients with Demodex blepharitis as possible.”
    Demodex blepharitis occurs when Demodex mites – the most common ectoparasites found on humans – overpopulate on the eyelids.
  • “Mite Party” will officially launch on the XDEMVY Facebook page (@xdemvyrx) with a live event designed to “break up the mite parties” on Demodex blepharitis patients’ eyelids.

Tarsus Announces Pricing of $100.0 Million Public Offering

Retrieved on: 
Vendredi, mars 1, 2024
Tarsus, Attention, Prospectus, Telephone, File, Floor, Sale, Exercise, Broad Street, Madison Avenue, Patient, BofA Securities, Science, Guggenheim Partners, Oppenheimer Holdings, TARS, Security (finance)

In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • In addition, Tarsus has granted the underwriters a 30-day option to purchase up to an additional 468,750 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Tarsus, are expected to be approximately $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares.
  • The offering is expected to close March 5, 2024, subject to the satisfaction of customary closing conditions.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Proposed $100.0 Million Public Offering

Retrieved on: 
Jeudi, février 29, 2024
Tarsus, Attention, Prospectus, Telephone, File, Floor, Sale, Broad Street, Madison Avenue, Patient, BofA Securities, Science, Guggenheim Partners, Oppenheimer Holdings, TARS, Security (finance)

Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.

Key Points: 
  • Tarsus also intends to grant the underwriters a 30-day option to purchase up to an additional $15.0 million of shares of its common stock offered in the proposed offering.
  • All securities in the proposed offering are to be sold by Tarsus.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • Goldman Sachs & Co. LLC, BofA Securities, Guggenheim Securities, LLC and Oppenheimer & Co. are acting as joint book-running managers for the offering.

Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept “Tick-Kill” Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease

Retrieved on: 
Jeudi, février 22, 2024
Lyme disease, Probability, Science, Mortality, Skin, Tick, Volunteering, Patient, TARS

Sterile, non-pathogenic nymphal ticks were placed on the skin of healthy human volunteers at two separate instances (one day prior to dosing and on Day 30 after dosing).

Key Points: 
  • Sterile, non-pathogenic nymphal ticks were placed on the skin of healthy human volunteers at two separate instances (one day prior to dosing and on Day 30 after dosing).
  • In most cases, ticks must be attached for 36-48 hours or more before Lyme disease can be transmitted, so killing ticks within 24 hours of attachment can greatly increase the probability of disease prevention 1.
  • Both the high and low doses of TP-05 demonstrated a statistically significant benefit in killing ticks compared to placebo.
  • No statistically significant differences in tick mortality were observed between the two TP-05 treatment arms, and TP-05 was generally well tolerated.

Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024

Retrieved on: 
Mardi, février 20, 2024
Science, Webcast, Patient, TARS

IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m.

Key Points: 
  • IRVINE, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize treatment for patients, starting with eye care, today announced that it will host a live webcast at 5 a.m. PT / 8 a.m.
  • ET on Tuesday, February 27, 2024 to report its fourth quarter and full year 2023 financial results and provide a corporate update.
  • Participants may access the webcast here .
  • A recorded version of the call will be available on the website shortly after the completion of the webcast and will be archived there for at least 90 days.